Regional Business Director, Hematology - East
Deciphera Pharmaceuticals
Umowa o pracęPełny etatOpublikowano 3 października 2026
Źródło: Deciphera, a member of Ono Pharmaceutical Co., Ltd., is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines and providing hope to people living with cancer, neurologic and autoimmune disease. Deciphera is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from Deciphera’s platform in clinical studies, QINLOCK® (ripretinib) is Deciphera’s switch-control kinase inhibitor approved in many countries including the European Union and the United States for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. ROMVIMZA® (vimseltinib) is a kinase inhibitor approved in the United States for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity, and in the European Union for adult patients with TGCT associated with clinically relevant physical function deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability.
The spirit of collaboration that has brought medications to life continues to guide how we operate, grow, and discover new breakthroughs. We cultivate an inclusive culture that values curiosity, creativity, and shared accountability—empowering individuals to challenge the unknown together.
Deciphera offers competitive compensation, including equity-based compensation, and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, life insurance and a flexible spending account for either health care and/or dependent care.
The Regional Business Director will prepare for the anticipated launch of tirabrutinib, a highly potent and selective Bruton tyrosine kinase (BTK) inhibitor being advanced for patients with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). PCNSL is a rare and aggressive extra-nodal non-Hodgkin lymphoma with significant unmet need, and tirabrutinib represents an important potential new treatment option for patients facing limited therapeutic choices.
The Regional Business Director will lead a regional sales team and play a critical role in shaping launch readiness by building regional business plans, developing team capabilities, and partnering closely with Market Access, Medical Affairs, Marketing, Commercial Operations, and other cross-functional stakeholders to prepare for a successful launch and support Deciphera’s efforts to bring tirabrutinib to patients in need.
Deciphera is committed to fair and equitable compensation practices. The base salary pay range for this role is $208,000 - $286,000. Actual compensation packages will depend on various factors, including, but not limited to depth of experience, education, skillset, overall performance and/or location.
The spirit of collaboration that has brought medications to life continues to guide how we operate, grow, and discover new breakthroughs. We cultivate an inclusive culture that values curiosity, creativity, and shared accountability—empowering individuals to challenge the unknown together.
Deciphera offers competitive compensation, including equity-based compensation, and a comprehensive benefits package that includes medical, dental, vision, 401(k) retirement plan, life insurance and a flexible spending account for either health care and/or dependent care.
The Regional Business Director will prepare for the anticipated launch of tirabrutinib, a highly potent and selective Bruton tyrosine kinase (BTK) inhibitor being advanced for patients with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). PCNSL is a rare and aggressive extra-nodal non-Hodgkin lymphoma with significant unmet need, and tirabrutinib represents an important potential new treatment option for patients facing limited therapeutic choices.
The Regional Business Director will lead a regional sales team and play a critical role in shaping launch readiness by building regional business plans, developing team capabilities, and partnering closely with Market Access, Medical Affairs, Marketing, Commercial Operations, and other cross-functional stakeholders to prepare for a successful launch and support Deciphera’s efforts to bring tirabrutinib to patients in need.
Deciphera is committed to fair and equitable compensation practices. The base salary pay range for this role is $208,000 - $286,000. Actual compensation packages will depend on various factors, including, but not limited to depth of experience, education, skillset, overall performance and/or location.
